Ads
related to: latest maintenance for ovarian cancer side effects
Search results
Results from the WOW.Com Content Network
Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults.It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.
In the European Union, niraparib is indicated: as monotherapy for the maintenance treatment of adults with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy; and as monotherapy for ...
Despite the encouraging results, there are not many clinical trials using metronomic therapy for ovarian cancer. Most of the findings are from case reports and pre-clinical trials. Due to few clinical trials and lack of information about the applications, it is still risky and questionable to substitute conventional therapy used in treatment of ...
Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. [5] [6] [10] Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.
The risk of type I ovarian cancer specifically was “especially high,” according to the study, at around 7.5-fold higher among women with endometriosis, and the risk of developing type II ...
A 25-year-old woman had pain in her side as a symptom of stage 2 low-grade serous ovarian cancer. She had a tumor on her ovary. Doctors said she was fine.
3. Medications. Some medications have been associated with temporary hair loss. Most of the time hair loss related to medication is due to the drug disrupting the hair growth cycle leading to a ...
[25] it started in 2013 a phase III for metastatic germline BRCA mutated breast cancer. [26] Veliparib June 2014 in phase III trials, for advanced ovarian cancer, triple-negative breast cancer and in non-small cell lung cancer (NSCLC). [27] Pamiparib (BGB-290) For ovarian cancer, 1st patient enrolled May 2018. [28] It is a PARP1 and PARP2 ...
Ads
related to: latest maintenance for ovarian cancer side effects